Hepatitis, Tuberculosis
Conditions
Brief summary
Tuberculosis is one of the major health problems in developing countries. Isoniazid, rifampin and pyrazinamide, the first line drugs used for tuberculosis chemotherapy, are associated with hepatotoxicity. The rate of hepatotoxicity has been reported to be much higher in developing countries compared to that in advanced countries with a similar dose schedule. Oxidative stress has proposed as one of the mechanisms responsible for anti-tuberculosis drugs induced hepatic injury. The oxidative stress is closely associated with decrease of glutathione levels. In the present study N acetylcysteine, a precursor of glutathione, was investigated for hepatoprotective effect against anti-tuberculosis drugs induced liver injury.
Interventions
DRUGN Acetylcysteine
1200 mg, BD, 2weeks
Sponsors
National Research Institute of Tuberculosis and Lung Disease, Iran
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Two sputum specimens positives for tubercle bacilli on direct smear microscopy * No previous anti-TB chemotherapy higher than two weeks * Aged 60 years and over * Agreement to participate in the study
Exclusion criteria
* Alcohol consumption * Viral disease (Hepatitis,...) * Abnormal pretreatment LFT level * Chronic disease (liver and kidney disease, asthma,...) * Additional hepatotoxic drug use * HIV positive * Liver TB * Patient in a moribund state * Hemoptysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatotoxicity | Two weeks |
Countries
Iran
Outcome results
None listed